Key result
Precision medicine and multi-omics frameworks offer transformative therapeutic potential for managing dyslipidaemia.
Why the study?
Dyslipidaemia remains a primary driver of atherogenesis and cardiovascular disease with complex pathophysiology and evolving diagnostic and therapeutic strategies requiring comprehensive synthesis.
Answers are grounded in this paper and cite their sources.
This comprehensive narrative review highlights recent paradigm shifts in molecular biology, advanced lipid biomarkers, and emerging RNA-targeted therapeutics for optimizing the management of dyslipidaemia.
Dyslipidaemia, characterized by aberrant circulating lipid and lipoprotein profiles, remains a primary driver of atherogenesis and cardiovascular disease (CVD), underlying substantial global morbidity and mortality. This review elucidates the complex pathophysiology, epidemiological dynamics, and genetic architectures defining dyslipidaemia, delineating primary hereditary molecular defects from secondary acquired etiologies. We highlight recent paradigms in molecular biology, advanced lipid biomarkers surpassing conventional lipid panels, and innovative imaging modalities that have collectively refined cardiovascular risk stratification and diagnostic precision. Furthermore, this work addresses the socioeconomic determinants and lifestyle factors that modulate prevalence and confound clinical management. Current therapeutic regimens—ranging from behavioral modifications and established pharmacological agents (statins, ezetimibe, and PCSK9 inhibitors) to emerging RNA-targeted therapeutics—are critically evaluated. We discuss persistent barriers to patient adherence and the transformative potential of precision medicine, driven by clinical genomics and targeted molecular interventions. Finally, we outline prospective paradigms integrating multi-omics frameworks, novel diagnostics, and psychosocial variables to mitigate the global burden of dyslipidaemia-mediated cardiovascular pathologies.
No takes yet. Share an insight, caveat, or question.
Qadir et al. (2026) conducted a review in Dyslipidaemia. This review evaluates the pathophysiology, epidemiology, and emerging therapeutic strategies for dyslipidaemia, highlighting the transformative potential of precision medicine and multi-omics frameworks.
Synapse has enriched 10 related papers. Consider them for comparative context: